SmartTab offering is now closed and is no longer accepting investments.

Future of Drug Delivery

INVEST IN SMARTTAB TODAY!

We believe SmartTab is a revolution in drug delivery for superior compliance, painless injections, and truly targeted medications. We are developing a platform of ingestible drug delivery technology that is moving through clinical studies, FDA approval process, and is targeting launch to market by 2024. This patient-driven SmartTab technology has the potential to ease the burden on patients with autoimmune diseases such as diabetes that require self-injections, providing patient-preferred delivery methods and monitoring capabilities.
... Show more
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
SmartTab

Reasons to Invest

  • LARGE GLOBAL MARKET: The size of the potential market for SmartTab is significant. There were 16 billion injections administered globally last year (Source). The world’s injectable market is expected to reach $931.1 billion by 2024 (Source).

 

  • MASSIVE PATIENT DEMAND: Based on our research and focus groups, there is significant demand from patients for SmartTab’s technology. We have seen that patients want to move away from daily or weekly self-injections to an oral delivery capsule platform. SmartTab received the 2021 Patients’ Choice Award by the Autoimmune Association.


  • TRACTION AND PROGRESS: We have completed lab validation and proof-of-concept through our first successful preclinical study. We are in the process of additional studies and an FDA submission, while building out a scale-up manufacturing facility and partnering with pharmaceutical companies to commercialize specific drug products.







PROGRESS OVERVIEW


The Future Here and Now

*Images are computer generated demo versions. Product is still currently under development.


SmartTab has developed a pipeline of capsule-sized ingestibles that incorporate advanced electronics and engineering for optimal drug delivery. The company is focused on launching InjectTab™ for oral delivery of biologics.




Scientists say smart tablets could improve the effectiveness of medications



We Believe the SmartTab Platform is the Most Significant Development in the Healthcare Management System in 200 Years

Our integrative team is composed of experienced engineers, pharmaceutical R&D and regulatory experts in a world-class facility for patient-centered innovation. Combining our backgrounds from the pharmaceutical and wireless medical device industries we developed the InjectTab™, what we believe to be a revolution in oral biologic drug delivery intended to replace the needle and syringe.


*Images are computer generated demo versions. Product is still currently under development.


InjectTab™ is a microneedle capsule with sensors and a microprocessor that we hope will confirm ideal positioning of the capsule and deliver life-saving biologic medication through an oral route of administration. Not only does our platform have the potential to deliver medicine less painfully and more effectively to the human body, we can obtain superior compliance and patient outcomes. We believe our team is well positioned in the industry to lead a new era of patient-centered drug delivery with strategic partners in the pharmaceutical industry and with the regulatory expertise to bring InjectTab™ technology to market by 2024.



Our Progress for Superior Compliance and Painless Injections Is Driven by Our Patient-centered Innovation





THE PROBLEM


Self-Injection of Biologics Are Painful and Invasive

(Source)


Large scale chronic diseases (i.e. Diabetes, Crohn’s Disease, Ulcerative Colitis, Psoriasis, Rheumatoid Arthritis, Cancer) are often treated with drugs that utilize a syringe or auto-injector. These administration methods can often cause stress, pain and anxiety which leads to poor adherence.


(Source)


You or someone you know may take an injection once a week or every day. Even though medicine itself has advanced, the way medication is delivered into the human body hasn't, and we are still stabbing ourselves with the antiquated needle and syringe technology.


Healthcare is increasingly happening at home and there is a lack of real-time monitoring within the current drug delivery technologies. SmartTab will be combining precision medication delivery with the latest sensor technology to communicate in real-time.

THE SOLUTION


Novel Ingestible Drug Delivery



 *Images are computer generated demo versions. Product is still currently under development


Over the last decade, Smartphones and wearable technology have transformed the delivery of healthcare. The same thing is now happening with pharmaceutical drug delivery systems leading us into the Decade of Ingestibles.


g

g

g

*Images above are computer generated demo versions. Product is still currently under development.




THE MARKET


Anticipated Launch into the Expected $931B Global Injections Market 


(Source, Source)


There are 16 billion injections administered every year around the world. The global injectable drug delivery market is expected to reach $931.1 billion by 2024. (Source, Source) Driving this growth is an increasing demand for minimally-invasive procedures— as well as better patient monitoring and outcome capabilities.


InjetTab™ will be launched into a pipeline of drug products starting with Insulin:


(Source, Source, Source)



THE BUSINESS MODEL


Partnering with Pharma to Launch



The SmartTab business model focuses on partnerships with pharmaceutical companies, we create the device and they provide the drug. SmartTab manufactures and supplies the capsules to pharma companies who load the capsules with their active ingredients and distribute through their channels—providing the patient with optimized therapies and superior outcomes. During the development process there are milestone payments as we move toward commercialization. Once commercialized, SmartTab will be paid by the pharmaceutical companies for the smart capsules.



THE VISION


Smart Pills for Optimized Therapies



Our Founder/CEO is planning to build upon his success with startup Nano Pharmaceutical Laboratories. He has a strong background directing research and development projects in the pharmaceutical space as a visionary entrepreneur on a mission to develop advanced drug delivery systems to improve patients' lives.


*Images are computer generated demo versions. Products are still currently under development.


SmartTab plans to pursue a phased platform approach for product development and commercialization. Each configuration is expected to be developed and commercialized, beginning with InjectTab™. The next capsules in the pipeline are TargetTab™ and MultiTab™. Future applications include diagnostics, surgical capsules, advanced endoscopes, pacemakers, and more.



WHY INVEST


Clear Line of Sight to Market



We believe SmartTab is leading the digital drug delivery revolution through patient-centered innovation, diligent engineering, and powerful partnerships with pharmaceutical companies. We believe the team is on a clear path to complete additional clinical studies, obtain FDA approval and bring InjectTab™ to market by 2024. We plan to advance care delivery for the 21st century—right here, right now.





ABOUT

HEADQUARTERS
3513 Brighton Blvd. Lab 310
Denver, CO 80216
VALUATION
$80M

We believe SmartTab is a revolution in drug delivery for superior compliance, painless injections, and truly targeted medications. We are developing a platform of ingestible drug delivery technology that is moving through clinical studies, FDA approval process, and is targeting launch to market by 2024. This patient-driven SmartTab technology has the potential to ease the burden on patients with autoimmune diseases such as diabetes that require self-injections, providing patient-preferred delivery methods and monitoring capabilities.

TEAM

Robert Niichel
Robert Niichel
CEO & Director

Robert Niichel is a healthcare entrepreneur and visionary. He is the Founder and CEO of SmartTab, a digital drug delivery company leading the development of wireless ingestible drug delivery technologies to dramatically improve patient outcomes. Niichel hosts a digital health innovation podcast called Who Would Have Thought.

Niichel started SmartTab in 2016 as an evolution of his prior startup company which brought pharmaceutical technologies into the sports nutrition and consumer healthcare space. Robert Niichel successfully raised capital, launched, and licensed this enterprise CPG company as the founder of Nano Pharmaceutical Laboratories. With over 20 years of experience of leadership and management in Pharmaceutical Research and Development, holding numerous pharma/delivery system patents issued and pending in the United States and Globally. He is educated with an MS in Biochemistry from the University of Colorado, Boulder.

Douglas Miller, PhD

Douglas Miller, PhD

Chief Technology Officer

Dr. Miller has 25+ years of experience in the medical device field including academic research and multi-national corporate R&D, as well as key roles in three previous start-ups where he was involved in founding and commercialization. Doug has 20+ years’ experience in active implantable devices and 5+ years in in vitro diagnostics and pharmaceuticals. He has led engineering, R&D, manufacturing, quality, and regulatory functions at the VP and director level, taking products from inception to market. He also holds nine patents in the biomedical field. Doug is a published author with a BS in Electrical Engineering and an MS & PhD in Electrical/Biomedical Engineering.

TERMS

SmartTab
Overview
PRICE PER SHARE
$4.87
DEADLINE
May 1, 2022
VALUATION
$80M
AMOUNT RAISED
$177,726.27
Breakdown
MIN INVESTMENT
$243.50
MAX INVESTMENT
$106,998.77
MIN NUMBER OF SHARES OFFERED
2,053
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
219,711

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Velóce Corporation

Corporate Address

:

3513 Brighton Blvd. Lab 310, Denver, CO 80216

Offering Minimum

:

$9,998.11

Offering Maximum

:

$1,069,992.57

Minimum Investment Amount

(per investor)

:

$496.74











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

2,053

Maximum Number of Shares Offered

:

219,711

Price per Share

:

$4.87

Pre-Money Valuation

:

$80,002,192.85











Voting Rights of Securities Sold in this Offering

Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Early Bird

Friends and Family - First 72 hours | 10% bonus shares

Super Early Bird - Next 72 hours | 5% bonus

Early Bird Bonus - Next 7 days | 3% bonus shares

 

Volume

Tier 1 - ($10,000+5% bonus shares)

Tier 2 - ($25,000 + 8% bonus shares)

Tier 3 - ($50,000+10% bonus shares)

*All perks occur when the offering is completed.

StartEngine Owner’s Bonus:

SmartTab will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $4.87/share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $487. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

In March 1994 Robert Niichel was barred from association with any NASD member in any capacity. Please refer to the Company’s Risk Factors for full disclosures.

PRESS

Article Image
Denver Business Journal

Coming soon: A pill that time-releases meds and records your body data

Article Image
IBD Journal

Advancing High Tech Drug Delivery Systems for the Treatment of Crohn’s Disease

Article Image
American Inno

Denver Startup Develops Smart Pill for Wireless Drug Delivery

Article Image
TechCrunch

SmartTab | Disrupt 2020

Article Image
Healthcare Goes Digital Podcast

When Wireless Technology Meets Drug Delivery










ALL UPDATES

05.03.22

Thank You! We Did It!


Dear SmartTab Investor Community,

Congratulations to everyone who invested during our equity crowdfunding campaign. We want to thank you for your partnership and commitment to advancing drug delivery technology.

On behalf of the entire SmartTab team, we’d like to extend our utmost gratitude and thanks to each and every one of our valued investors, supporters, friends and family. We’re absolutely thrilled by what we’ve achieved, opening up investments to individual investors and raising a total of $177,726 from 97 investors. Thank you for all the support we’ve received—from phone calls, emails, and texts. We will stay in touch along the way as we target larger strategic funding and advance SmartTab technology. Look out for our monthly investor only email updates and quarterly webinars. 

We are excited for this next chapter of SmartTab as we take our efforts to the next level to move our technology through clinical studies and FDA process.  We are on the leading edge of discovery alongside the most talented individuals in the area of wireless technology and pharmaceutical drug delivery. Thank you to our entire team for their tireless work over the years since beginning this journey, and this equity crowdfunding capital raise is a validation of our progress and determination. We are well on our way to achieving our goal of building the future of drug delivery together for patients.

We appreciate each and every one of you for believing in us and joining our journey to bring this cutting-edge technology to every patient and evolve the experience of drug delivery to one that is deserving of the 21st century.

Thank you!

04.30.22

Only 12 Hours Left to Invest!



SmartTab's equity crowdfunding campaign giving individuals an opportunity to own a stake is officially closing on StartEngine. Only 12 hours left to stake your claim in transformative drug delivery technology as this equity crowdfunding campaign is ending.

Join us on our journey to bring this cutting-edge technology to every patient and evolve the experience of drug delivery to one that is deserving of the 21st century.

Now is the time to Top-up your investment or become an investor before it is too late.

Please complete your investment by clicking the link below.

Click Here to Invest


04.29.22

✨ Final Hours to Invest!

Dear SmartTab Investor Community,

As this equity crowdfunding campaign comes to an end. We look back on all the milestones and progress we've made in the last quarter and beyond. We've come this far from concept to reality thanks to passionate investors like you. We appreciate each and every one of you for believing in us and joining  our journey to transform a significant patient need. This is the beginning of a new chapter for SmartTab as we now focus on forwarding our intellectual property, conversations with the FDA, pharmaceutical partnerships, completing InjectTab™ preclinical studies and raising large strategic funding to reach commercialization. This is a mission, we are doing this for patients and for humanity. Everyday we continue to make progress and now we accelerate our efforts to build the future of drug delivery together. 

✨ Lab Facility in Health Tech Innovation Center in Denver and Plans in Place for Expansion to Larger Manufacturing Facility

✨ InjectTab™ Gastric Environment Validation Process Completed

✨ Successful TargetTab™ Animal Study and InjectTab™ Preclinical Study Underway for Summer 2022

✨ Currently in Dialogue with FDA: Pre-Submission In-Progress

✨ Total of 3 Patents Issued, 5 Patents Pending - Most Recent Patent Issued Jan. 2022

✨ Successful Startup Health Festival @ ViVE Conference 

✨ SXSW Pitch Finalist,  CEO of SmartTab Recognized on Denver Business Journal

✨ Named Top 100 Digital Health Companies by Medical Futurist

✨ Completed PharmStars Accelerator to Advance Digital-Pharma Partnerships

You still have time to top-up your investment or become an investor before it is too late!

Visit the link below to complete your investment today.

Click Here to Invest

04.29.22

Intellectual Property Update: "Wireless Communications System Integrating Electronics Into Orally Ingestible Products for Controlled Release of Active Ingredients"

Dear SmartTab Investor Community,

With only 1 day left to invest in SmartTab on StartEngine we thought it would be great to take a deep dive into our intellectual property. We have been aggressive with our IP and already have 3 patents issued to date with 5+ currently pending. Your investment fuels our work with the best in the industry for obtaining intellectual property rights and using those rights to protect and promote SmartTab as we grow. 


"Wireless Communications System Integrating Electronics Into Orally Ingestible Products for Controlled Release of Active Ingredients"


Now is the time to top-up your investment or become an investor before it is too late. So far, we have raised $169,919 from 90 investors. We are so thankful for all of our investors so far, and look forward to the growth that would not be possible without your investment. Visit the link below to complete your investment today.

Click Here to Invest

04.28.22

Only 2 Days Left to Invest!

Dear SmartTab Investor Community,

These are the final moments to stake your claim in SmartTab's drug delivery technology. We want to thank all of you for participating and believing in our team. Join us in advancing our InjectTab technology for delivery of biologics and large molecules to create a significant shift in drug delivery. Listen in to our Founder and CEO on the Health Innovators show. Patient co-creation: How to play the long game with novel tech in healthcare w/ Robert Niichel. 


This is your final opportunity to contribute to the advancement of drug delivery systems and improving the patient lives. 

Visit the link below to complete your investment today.

Click Here to Invest

04.28.22

Business Update: Reducing Capsule Size

Dear Investor Community,

As we move into preclinical studies with InjectTab, we are reducing the capsule size from 000 to 00.

InjectTab is currently based on the 000 size capsule highlighted above but by leveraging miniaturization techniques, we believe that 00 and 0 size InjectTab capsules are viable throughout development and commercialization.

Join our investor community while you still can. ⏰ There are only 2 days left to invest in our Reg CF offering, and a minimum investment makes you eligible for the StartEngine Owner’s Bonus of 10% bonus shares. These are the hours to stake your claim in SmartTab’s transformative drug delivery technology. Visit the link below to complete your investment.

Click Here to Invest

04.27.22

🎥 LIVE on Startup Health TV With Only a Couple of Days Left to Invest in SmartTab!

Dear SmartTab Investor Community,

SmartTab, joined Startup Health in 2016, on a mission to provide patient-centered wireless precision drug delivery to every patient, in every household, in every country, bringing advanced drug delivery systems to market to optimize patient care. Watch this candid interview with Chief Marketing Officer of SmartTab LIVE on Startup Health TV during the ViVE conference. This interview covers InjectTab and the patient preferred oral method of delivery for biologics, realtime monitoring to optimize the medication delivery and the importance of bringing this technology to market. 

As we enter the final 3 days of our StartEngine raise, we want to thank each and everyone of you who invested so far. This is your opportunity to invest and hold a stake in the transformation of drug delivery technologies. Now is the time to top-up your investment or become an investor before it is too late. Please complete your investment by clicking the link below.

Click Here to Invest

04.26.22

4 Days Left Invest in SmartTab 🏁

Dear Investor Community,

SmartTab is developing inner body technology to transform how we diagnose and treat chronic disease. A pharmaceutical product line focused on improving patient adherence and outcomes, enhancing remote patient monitoring and IoMT, optimizing clinical efficacy, and patient treatment plans. 

These are the final days to stake your claim in our transformative drug delivery technology and profit when the company does well. Now is the time to top-up your investment or become an investor before it is too late. Don't miss your chance to claim your piece of ownership! Please complete your investment by clicking the link below.

Click Here to Invest


Watch the recordings of SmartTab’s investors’ webinar series. The webinar is a remarkable opportunity to get involved early and learn more about how SmartTab will transform healthcare and patients’ lives for the better.

Watch the Webinar Recordings

04.25.22

5 Days Left to Invest in SmartTab!

Dear Investor Community, 

Only 5 days left to invest in SmartTab so here are our top 5 reasons to invest: 

  • Large Global Market: The world’s injectable market is expected to reach $931.1 billion by 2024
  • World-class Team: CEO with 25+ years in Pharmaceutical R&D and CTO 30+ Years in Med Device / Pharmaceuticals
  • Preclinical Studies: Already completed one successful preclinical study moving into additional studies this Summer
  • Addressing Patient Needs: We received the Patients' Choice Award and are addressing significant needs around drug delivery. 
  • Partnership Traction: We completed PharmStars and are partnering with Pharmaceutical companies to bring this technology to market. 

Here's a video that demonstrates the InjectTab™ and the capsule functioning in the lab beaker:


The SmartTab team made a visit to our CRO for the preclinical studies last week to prepare for a PK study with the InjectTab™ this summer. SmartTab will be expanding to a larger manufacturing facility by the end of the year to build out larger quantities for upcoming clinical studies. What was once an idea is becoming a reality and we can't do it without passionate investors like you. Together we can transform the future of drug delivery and improve patient lives. Don't miss your chance to be an early investor and claim your piece of ownership! Please complete your investment by clicking the link below. 

Click Here to Invest

04.23.22

🚀 Offering Closing Soon—Invest in the Future of Drug Delivery!

Dear Investor Community,

This is the final week for individuals to invest before we move on to larger strategic funding. We are so thankful for all of our investors so far. Patients can't wait for this technology, as Patient Advisor of SmartTab speaks about below in a snippet from our webinar on Thursday. 

Now is the time to top-up your investment or to become an investor before it is too late. There are only 7 days left to invest in our Reg CF offering, and a minimum investment of just $250 makes you eligible for the StartEngine Owner’s Bonus of 10% bonus shares.  Visit the link below to complete your investment today.

Click Here to Invest










REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into SmartTab.

$496.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$10,000.00

Tier 1

($10,000+5% bonus shares)

$25,000.00

Tier 2

($25,000 + 7.5% bonus shares)

$50,000.00

Tier 3

($50,000+10% bonus shares)

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.